# Combination Study of Antibiotics With Enzalutamide (PROMIZE)

> **NCT06126731** · PHASE1,PHASE2 · RECRUITING · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 39 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Enzalutamide 40mg
- **DRUG:** Amoxicillin 500mg
- **DRUG:** Metronidazole 400mg
- **DRUG:** Vancomycin 125mg
- **DRUG:** Ciprofloxacin 500g

## Key facts

- **NCT ID:** NCT06126731
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-02
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126731, "Combination Study of Antibiotics With Enzalutamide (PROMIZE)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06126731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*